Australian Prime Minister Anthony Albanese has revealed that one of his closest friends, Chris Raper, died on Monday after a battle with dementia.
Albanese shared the news during an interview with ABC Breakfast, reflecting on the personal loss. Raper was a significant figure in the Labor party, having served as the state secretary of the Miscellaneous Workers Union and held senior positions in the governments of former NSW premiers Bob Carr and Morris Iemma.
"I lost a good friend of mine who passed away on Monday," Albanese stated. "Chris Raper, who was a union official in the Miscellaneous Workers Union and a dear friend. He was severely affected, as so many Australians are, by dementia."
The Prime Minister's announcement came as Health Minister Mark Butler was preparing to open the Asia Pacific Centre for Excellence on Alzheimer's Disease in Sydney. Researchers at the new facility hope to advance the diagnosis of Alzheimer's disease through a new blood test.
Albanese emphasized the importance of such advancements, particularly in early detection. "This could be a massive breakthrough, essentially a blood test for early detection," he said. "This is a tragedy that can hit so many families, and this breakthrough today is really important and provides hope at a time where I think the world needs more hope and less fear as we go forward."
The newly approved blood test can detect key markers associated with Alzheimer's disease, including the proteins amyloid and tau, which accumulate in the brain years before symptoms manifest. This non-invasive test offers a potential alternative to the current diagnostic methods, which typically involve lumbar punctures or expensive, less accessible brain scans.
Associate Professor Emma Devenney, a neurologist at NeuRA who will oversee the new center, noted the significance of early detection. "Earlier is definitely better for people who have symptoms," Devenney said. "It's really important for people to plan while they still can, to give them time to do the things that they want to do."
The test, approved by the Therapeutic Goods Administration, is slated for further clinical trials. If successful, it is expected to be available through specialist referral across Australia by the end of the year, with eventual accessibility through Medicare. However, Devenney cautioned that initially, the test would likely be available to individuals already exhibiting symptoms, as it detects the biological changes associated with Alzheimer's rather than definitively diagnosing the disease at a specific future onset. Further development is needed to provide a clearer timeline for symptom development.
